Application | Comment | Organism |
---|---|---|
medicine | the efficacy of recombinant factor VIIa for the reversal of anticoagulation in patients with warfarin-associated intracranial hemorrhage is described in several case reports, case series, and retrospective cohort studies. Its use may be considered for as a viable alternative treatment to standard treatment with fresh-frozen plasma. Patients should be screened for increased risk of thrombosis before administration of the drug | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|
Synonyms | Comment | Organism |
---|---|---|
factor VIIa | - |
Mus musculus |
factor VIIa | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | eosinophil counts in the bronchoalveolar lavage fluid of wild-type mice increases after ovalbumin challenge, a response that is diminished in comparably challenged low-expressing coagulation factor VII (FVIItTA/tTA) mice. Levels of T helper type 2 cytokines, IL-4, IL-5, and IL-13, and eosinophil-attracting chemokines, eotaxin and RANTES, are also lower in the ovalbumin-challenged low expression factor VIIa mice. Eosinophils purified from low-FVII mice undergo apoptosis at a faster rate compared with wild-type eosinophils, and eosinophil migration in response to eotaxin is reduced in eosinophils obtained from low expressing factor VIIa mice. Airway hyperresponsiveness and mucous layer thickness are reduced in ovalbumin-treated low expressing factor VIIa mice | Mus musculus |